Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

mUC

- PMLiVE

Gilead’s Trodelvy plus Keytruda shows positive results in metastatic breast cancer

The combination treatment showed a 35% reduction in the risk of disease progression

- PMLiVE

Pfizer’s PADCEV gets FDA approval for bladder cancer

Bladder cancer affects more than 614,000 people globally each year

- PMLiVE

MSD receives NICE recommendation for Keytruda in advanced endometrial cancer

More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK

- PMLiVE

Merck unveils $3bn cost-cutting plan to support pipeline and new product launches

A new restructuring programme has been approved to support the initiative

- PMLiVE

Johnson & Johnson’s TAR-200 granted FDA priority review to treat bladder cancer

An estimated 84,870 people will be diagnosed with bladder cancer in the US this year

- PMLiVE

AstraZeneca’s Imfinzi regimen approved by EC to treat muscle-invasive bladder cancer

More than 35,000 people in five major European countries were treated for the disease last year

- PMLiVE

Merck’s perioperative Keytruda regimen approved by FDA for head and neck cancer

More than 72,680 new cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

AstraZeneca receives CHMP recommendation for Imfinzi regimen in bladder cancer

More than 614,000 cases of bladder cancer are diagnosed globally every year

- PMLiVE

Merck shares promising phase 3 results for Keytruda in ovarian cancer

Approximately 20,890 cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

MSD receives MHRA approval for adult-specific pneumococcal vaccine Capvaxive

Illnesses caused by Streptococcus pneumoniae are currently considered a major public health problem by WHO

- PMLiVE

Johnson & Johnson’s bladder cancer therapy Balversa accepted by SMC

Almost 1,700 people are diagnosed with bladder cancer in Scotland annually

- PMLiVE

AstraZeneca announces positive phase 3 results for Imfinzi in high-risk bladder cancer

Around half of NMIBC patients are classed as being high-risk for disease progression or recurrence

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links